Checkpoint Therapeutics (NASDAQ:CKPT) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $20.00 price objective on the stock.

Checkpoint Therapeutics Stock Down 1.2 %

Shares of NASDAQ:CKPT opened at $2.43 on Monday. Checkpoint Therapeutics has a 52 week low of $1.30 and a 52 week high of $3.62. The company has a 50-day moving average price of $2.33 and a 200 day moving average price of $2.03. The company has a market cap of $86.72 million, a P/E ratio of -0.88 and a beta of 1.29.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.11. The business had revenue of $0.04 million during the quarter. Analysts expect that Checkpoint Therapeutics will post -0.81 EPS for the current year.

Insider Transactions at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 13,038 shares of the stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total value of $26,858.28. Following the sale, the chief financial officer now directly owns 672,186 shares of the company’s stock, valued at approximately $1,384,703.16. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 24,610 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $2.05, for a total transaction of $50,450.50. Following the sale, the chief executive officer now directly owns 1,977,170 shares of the company’s stock, valued at approximately $4,053,198.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William Garrett Gray sold 13,038 shares of the company’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $2.06, for a total transaction of $26,858.28. Following the transaction, the chief financial officer now directly owns 672,186 shares in the company, valued at approximately $1,384,703.16. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CKPT. PVG Asset Management Corp purchased a new stake in Checkpoint Therapeutics in the 2nd quarter valued at about $295,000. B. Riley Wealth Advisors Inc. grew its holdings in Checkpoint Therapeutics by 366.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after purchasing an additional 180,050 shares during the period. XTX Topco Ltd purchased a new stake in Checkpoint Therapeutics in the second quarter valued at approximately $34,000. Choreo LLC increased its position in Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock worth $133,000 after purchasing an additional 7,080 shares during the last quarter. Finally, 180 Wealth Advisors LLC purchased a new position in Checkpoint Therapeutics during the second quarter worth approximately $96,000. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.